Document is current
Any future updates will be listed below
-
Authors
Hagy, Hannah
Hidalgo-Lopez, Esmeralda
Portengen, Christel
Holman, Alexis
Schrepf, Andrew
Clauw, Daniel J.
Harte, Steven E.
Beltz, Adriene M.
Bohnert, Amy M.
Kaplan, Chelsea M.
-
Funding
Funding for this research was provided by:
National Institute of Nursing Research (R01 NR020013)
National Institute of Nursing Research (R01 NR020013)
National Institute of Nursing Research (R01 NR020013)
National Institute of Nursing Research (R01 NR020013)
National Institute of Nursing Research (R01 NR020013)
National Institute of Nursing Research (R01 NR020013)
National Institute of Nursing Research (R01 NR020013)
- License Information
-
More Information
Article History
Received: 1 April 2025
Accepted: 6 October 2025
First Online: 4 November 2025
Declarations
:
: Not applicable.
: Not applicable.
: Dr. Harte reported receiving grant support from Arbor Medical Innovations, personal fees from Wayne State University, Memorial Sloan Kettering Cancer Center, Indiana University and Dana Farber Cancer Institute and having a patent for US9307906B2 licensed to Arbor Medical Innovations. Dr. Clauw reported receiving consulting fees from AbbVie Inc., Allergan Sales LLC, Heron Therapeutics, Inc., Eli Lily and Company, Aptinyx, Inc., H. Lundbeck A/S, Neumentum, Inc., Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Samumed, LLC, Swing Therapeutics, Inc., Tonix Pharmaceuticals, Inc., Virios Therapeutics, Inc., and payment for expert testimony from Fasken Martinueau DuMoulin LLP, Kellog, Hansen, Todd, Figel & Fredierick PLLC, Marks & Clerk Law LLP, Nix Paterson LLP, Pfizer, Inc., and Zuber Lawler & Del Duca LLP.
